Company Overview
Neumora Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases within the United States market. The company's primary asset is navacaprant (NMRA-140), which is engineered as a novel once-daily oral kappa opioid receptor agonist designed to address these specific neurological conditions. This business model places Neumora within the Healthcare sector, specifically the Biotechnology industry, a classification that signifies the firm is in a pre-revenue or early commercialization phase where success depends heavily on clinical trial outcomes rather than established sales pipelines. The company currently maintains a market capitalization of $424.85M and employs 95 individuals to execute its research and development strategy. These financial figures indicate that Neumora is a mid-cap entity with significant valuation relative to its current employee base, suggesting a high concentration of resources allocated to advancing its single primary therapeutic candidate before achieving substantial commercial revenue generation.
Financial Health
The company's financial statements reflect a pre-profitability stage, reporting revenue and earnings growth figures that are currently unavailable due to the lack of significant commercial sales, with net income (TTM) standing at $-236,296,992 and EBITDA at $-240,242,000. The substantial gap between the reported revenue (which is N/A) and the large negative net income reveals a cost structure dominated by research and development expenditures typical of clinical-stage biotechnology firms. Consequently, the company generates negative free cash flow of $-120,069,128, indicating that cash outflows for operations and capital expenditures exceed cash inflows, which limits immediate financial flexibility but is often a necessary condition for drug development. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, a standard presentation for companies with no revenue that indicates the inability to calculate margins in the traditional sense until product launch. Despite these operating losses, Neumora holds $171.52M in cash against $20.09M in debt, resulting in a debt-to-equity ratio of 15.20. While the debt-to-equity figure appears high, the balance sheet is supported by a robust cash reserve that significantly outweighs total liabilities, providing a conservative liquidity position relative to the magnitude of its cash on hand. The current ratio stands at 6.85, a figure that indicates strong short-term liquidity and a substantial buffer to cover current liabilities with current assets. Furthermore, the Return on Equity is -104.3% and the Return on Assets is -56.7%, metrics that reveal management is currently deploying capital to generate negative returns in the short term as they prioritize asset accumulation and clinical progression over immediate profitability.
Valuation Assessment
Valuation metrics for Neumora present a complex picture due to the absence of earnings, with the P/E Ratio (TTM) listed as N/A and the Forward P/E at -2.51. The negative forward P/E implies that the market is pricing in future earnings that are expected to turn the company positive, though the difference between the trailing and forward metrics suggests a transition phase rather than established profitability. The price-to-book ratio is 3.06, indicating that the market values the company at more than three times its book value, which reflects a premium assigned to the intangible value of its drug pipeline and intellectual property. Alternative valuation metrics such as the price-to-sales ratio (N/A) and EV/EBITDA (-1.11) further highlight the company's reliance on non-earnings-based valuation methods common for pre-commercial biotech firms. In terms of trading range, the stock has a 52-week high of $3.65 and a 52-week low of $0.61, and without a specific current price provided in the facts, the valuation context relies on the established volatility within this wide range. The beta value is 2.53, which explains that the stock price exhibits high volatility relative to the broader market, moving more than twice as much as the average stock in response to market fluctuations.
Growth & Income
The company's revenue growth (YoY) and earnings growth (YoY) are both listed as N/A, reflecting the fact that Neumora has not yet generated sufficient commercial revenue to calculate year-over-year growth rates or to establish a historical earnings trajectory. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm does not distribute cash to shareholders but instead retains all available capital to reinvest into its clinical programs and operational growth. This reinvestment strategy is typical for clinical-stage biopharmaceutical companies that must allocate substantial cash reserves to fund ongoing research, development, and potential future acquisitions rather than providing income to investors. The overall growth and income profile is defined by a complete reliance on capital markets for funding and a focus on long-term value creation through the successful development of navacaprant rather than immediate financial returns or dividend distributions.